Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.

Trial Details

NCT ID
NCT06343402
Phase
PHASE1
Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • BBO-8520
  • Pembrolizumab
  • BBO-10203
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • La Jolla, California, United States|32.84727,-117.2742
  • San Francisco, California, United States|37.77493,-122.41942
  • Santa Monica, California, United States|34.01949,-118.49138
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Histologically documented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation
  • Measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →